A longevity platform just put three compounded peptides on the menu — including one your mitochondria make

Edited by Samael A. Tejada, Founder & Editor-in-Chief

One of the three new offerings is unusual: MOTS-c is not a copy of a hormone but a peptide encoded in mitochondrial DNA itself. The launch is a market and policy story first — and the company, to its credit, says so in its own fine print.

What exactly launched?

Clinician-guided injectable peptide plans for BPC-157, TB-500 and MOTS-c, joining AgelessRx's existing lineup (Sermorelin, PT-141, GHK-Cu Cream). The peptides are available to eligible adults after review by a licensed medical provider. BPC-157 is a synthetic peptide based on a compound found naturally in the stomach; TB-500 is a synthetic fragment of thymosin beta-4, a peptide involved in cell movement and tissue repair; MOTS-c is encoded by mitochondrial DNA and is studied for its role in metabolic regulation — the direct mitochondria connection of the three.

How can unapproved peptides be sold at all?

Through compounding law, not approval. In July 2026 an FDA advisory committee reviewed seven peptides for possible inclusion on the 503A Bulks List — the ingredients licensed pharmacies may compound from. On October 30, 2026, the FDA issued an interim policy stating it does not currently intend to take enforcement action against licensed 503A compounding pharmacies preparing six of those peptides, including all three launched here, while its review completes. That is enforcement discretion: it is not an FDA approval, it does not mean the FDA has found any of these peptides safe or effective, and it may change.

What does the evidence actually support?

Less than the marketing around peptides generally suggests. Human evidence for BPC-157, TB-500 and MOTS-c is preliminary and limited; none is an FDA-approved drug for any use. AgelessRx evaluates products under its own public Peptide Standard and rates all three Tier 3 Investigational — the company's own signal that these are early-evidence products. Readers weighing a plan should hold both facts at once: access is real and now formally tolerated for compounding, and proof of benefit is not.

Where the evidence stands

• Established: MOTS-c is a peptide encoded in mitochondrial DNA. Compounded medications are not FDA-approved, and the October 30, 2026 interim policy is enforcement discretion, not approval.
• Preliminary: Any benefit of BPC-157, TB-500 or MOTS-c in people: early, limited human data; the company's own standard rates all three Tier 3 Investigational.
• Absent: FDA findings of safety or effectiveness for any of the three peptides, for any use.